| 1 |
geometric mean fold rise
(24 times)
|
Allergy and Immunology
(15 times)
|
GMT (12 times)
VZV (12 times)
AEs (7 times)
|
2007 Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.
|
| 2 |
geometric fold rise
(1 time)
|
Allergy and Immunology
(1 time)
|
AE (1 time)
HCT (1 time)
HM (1 time)
|
2017 Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies.
|
| 3 |
geometric mean fold rise from baseline
(1 time)
|
Communicable Diseases
(1 time)
|
AEs (1 time)
CI (1 time)
gpELISA (1 time)
|
2017 Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
|
| 4 |
geometric mean functional relationship
(1 time)
|
Pharmacology
(1 time)
|
ML (1 time)
PLS (1 time)
RMSE (1 time)
|
2000 Non-linear regression analysis with errors in both variables: estimation of co-operative binding parameters.
|
| 5 |
geometric mean severalfold rise
(1 time)
|
Allergy and Immunology
(1 time)
|
Ab (1 time)
CI (1 time)
LB (1 time)
|
2009 Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older.
|
A Search Service for Abbreviation / Long Form